免疫调节药物与Cereblon E3连接酶调节剂在多发性骨髓瘤中的三十年历程
本文综述免疫调节药物(IMiDs)三十年发展,从沙利度胺偶然应用、来那度胺确立Rd骨架与维持范式、泊马度胺在来那度胺失败后仍有效,到新一代Cereblon E3连接酶调节剂(CELMoDs)iberdomide和mezigdomide克服耐药,并讨论其与单抗、双抗、CAR-T的合理联合及在免疫治疗时代的定位框架。
要点
- IMiDs贯穿诱导、复发和维持治疗,延长生存并建立持久骨架。
- Cereblon作为可成药E3连接酶底物受体,为下一代调节剂提供机制路径。
- CELMoDs旨在加深Cereblon调节并克服IMiD难治、三药暴露疾病的耐药。
核心结论
- IMiDs已根本性重塑多发性骨髓瘤治疗,延长生存并建立持久骨架。
- Cereblon识别为可成药E3连接酶底物受体,开辟下一代调节剂机制路径。
- CELMoDs设计用于加深Cereblon调节并克服耐药。
研究设计与样本
- 本综述将IMiD类的临床演变与其机制基础相联系。
- 追溯从沙利度胺偶然重定位到来那度胺Rd骨架与维持范式及泊马度胺的路径。
主要发现
- 来那度胺广泛一线暴露产生对IMiD难治、三药暴露疾病可扩展口服药物的临床需求。
- 泊马度胺在来那度胺失败后仍保留疗效。
- 结构生化见解显示药物化学重塑Cereblon结合与选择性新底物降解,产生肿瘤内在和免疫介导效应。
临床怎么用
- 总结CELMoDs早期临床经验与正在进行的随机程序。
- 讨论与单克隆抗体、双特异性T细胞衔接器和嵌合抗原受体T细胞疗法的合理联合。
- 提出在免疫治疗丰富时代定位CELMoDs的务实框架。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immunomodulatory drugs (IMiDs) have fundamentally reshaped multiple myeloma therapy, extending survival and establishing durable backbones across induction, relapse, and maintenance. Cereblon's identification as a druggable E3 ligase substrate receptor created the mechanistic path to next-generation modulators, whereas widespread frontline lenalidomide exposure created the clinical need for scalable oral agents active in IMiD-refractory, triple-class-exposed disease. In this review, we link the clinical evolution of the IMiD class to its mechanistic foundation. We trace the path from thalidomide's serendipitous repurposing to lenalidomide's establishment of the Rd backbone and maintenance paradigm and to pomalidomide's ability to retain efficacy after lenalidomide failure. We integrate structural and biochemical insights showing how medicinal chemistry reshaped cereblon engagement and selective neosubstrate degradation, producing tumor-intrinsic and immune-mediated effects. We then focus on next-generation cereblon E3 ligase modulators (CELMoDs), including iberdomide and mezigdomide, designed to deepen cereblon modulation and overcome resistance. We summarize early clinical experience and ongoing randomized programs, discuss rational combinations with monoclonal antibodies, bispecific T-cell engagers, and chimeric antigen receptor T-cell therapies, and propose a pragmatic framework for positioning CELMoDs in an immunotherapy-rich treatment era.
引用
- Bazarbachi AH, Lentzsch S, Facon T, et al. Immunomodulatory Drugs and Cereblon E3 Ligase Modulators in Multiple Myeloma: 30 Years in the Making. J Clin Oncol. 2026. PMID: 42721415. doi:10.1200/JCO-26-00545
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。